Steering tumor progression through the transcriptional response to growth factors and stroma

Morris E Feldman1, Yosef Yarden1

  • 1Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel.

FEBS Letters
|May 31, 2014
PubMed

Insights

Tumor progression involves growth factors and mutations. A timed gene expression program, triggered by epidermal growth factor receptor (EGFR) signaling, drives cell changes and potential cancer development.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Tumorigenesis is driven by genetic mutations and growth factor signaling.
  • Epidermal Growth Factor Receptor (EGFR) signaling plays a crucial role in cell proliferation and invasion.
  • Understanding the temporal dynamics of gene expression is key to deciphering cancer progression.

Purpose of the Study:

  • To elucidate the sequential transcriptional events initiated by growth factor stimulation, focusing on EGFR signaling.
  • To identify key regulatory nodes within this dynamic gene expression program.
  • To explore the potential of these regulatory steps as targets for cancer therapy.

Main Methods:

  • Analysis of gene expression patterns following growth factor stimulation.
  • Focus on microRNA dynamics and the induction of immediate early genes (IEGs), delayed early genes, and late response genes.
  • Investigating signaling pathways downstream of EGFR.

Main Results:

  • A wave-like transcriptional program was identified, starting with microRNA downregulation.
  • This is followed by sequential upregulation of immediate early genes, delayed early genes, and finally, persistent late response genes.
  • This temporal cascade influences long-term cellular phenotypes like invasiveness.

Conclusions:

  • Growth factor-induced signaling orchestrates a precise, multi-wave gene expression program.
  • This program is critical for driving tumor progression and phenotypic changes.
  • Key regulatory points in this cascade represent potential therapeutic targets for oncogenes and tumor suppressors.

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Tumor Progression02:07

Tumor Progression

3.1K